AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives

[1]  M. Caulfield,et al.  Use of whole genome sequencing to determine genetic basis of suspected mitochondrial disorders: cohort study , 2021, BMJ.

[2]  S. Gray,et al.  Adeno-associated viral vector serotype 9-based gene replacement therapy for SURF1-related Leigh syndrome , 2021, Molecular therapy. Methods & clinical development.

[3]  G. Gao,et al.  Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency , 2021, Annals of neurology.

[4]  Gene therapies should be for all , 2021, Nature Medicine.

[5]  A. Zamyatnin,et al.  Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification , 2021, Pharmaceutics.

[6]  S. Priglinger,et al.  Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders , 2021, EMBO molecular medicine.

[7]  Johannes C. M. van der Loo,et al.  The clinical landscape for AAV gene therapies , 2021, Nature Reviews Drug Discovery.

[8]  J. Sahel,et al.  Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset. , 2021, Ophthalmology.

[9]  S. Paul,et al.  Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning , 2020, Molecular therapy. Methods & clinical development.

[10]  David J. Calkins,et al.  Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy , 2020, Science Translational Medicine.

[11]  S. Lope-Piedrafita,et al.  Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosides , 2020, EBioMedicine.

[12]  F. Bushman,et al.  A long-term study of AAV gene therapy in hemophilia A dogs identifies clonal expansions of transduced liver cells , 2020, Nature Biotechnology.

[13]  S. Subramony,et al.  Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study) , 2020, Annals of neurology.

[14]  K. Xue,et al.  Genome-Editing Strategies for Treating Human Retinal Degenerations , 2020, Human gene therapy.

[15]  A. Philippidis.  After Third Death, Audentes' AT132 Remains on Clinical Hold. , 2020, Human gene therapy.

[16]  L. Monassier,et al.  High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models , 2020, Molecular therapy. Methods & clinical development.

[17]  High-dose AAV gene therapy deaths , 2020, Nature Biotechnology.

[18]  J. Rahman,et al.  Moving towards clinical trials for mitochondrial diseases , 2020, Journal of inherited metabolic disease.

[19]  S. Lacroix-Desmazes,et al.  IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies , 2020, Nature Medicine.

[20]  David R. Liu,et al.  A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing , 2020, Nature.

[21]  J. Auwerx,et al.  Gene replacement therapy provides benefit in an adult mouse model of Leigh syndrome. , 2020, Brain : a journal of neurology.

[22]  M. Zeviani,et al.  A Single Intravenous Injection of AAV-PHP.B-hNDUFS4 Ameliorates the Phenotype of Ndufs4−/− Mice , 2020, Molecular therapy. Methods & clinical development.

[23]  Vassilios J. Bezzerides,et al.  AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome , 2020, Circulation research.

[24]  G. Enns,et al.  Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). , 2020, Molecular genetics and metabolism.

[25]  Yidong Bai,et al.  Emerging model systems and treatment approaches for Leber's hereditary optic neuropathy: Challenges and opportunities. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[26]  R. Samulski,et al.  Engineering adeno-associated virus vectors for gene therapy , 2020, Nature Reviews Genetics.

[27]  Yueh-Chiang Hu,et al.  Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46-/- mice. , 2020, Human molecular genetics.

[28]  Patrizia Tornabene,et al.  Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes? , 2020, Human gene therapy.

[29]  C. Moraes,et al.  Myopathy reversion in mice after restauration of mitochondrial complex I , 2020, EMBO molecular medicine.

[30]  P. Ping,et al.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome. , 2020, Gene.

[31]  O. King,et al.  Ly6a differential expression in BBB is responsible for strain specific CNS transduction profile of AAV-PHP.B. , 2019, Human gene therapy.

[32]  C. Karaarslan.  Leber’s Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development , 2019, Advances in Therapy.

[33]  S. Bidichandani,et al.  Friedreich ataxia- pathogenesis and implications for therapies , 2019, Neurobiology of Disease.

[34]  A. Khandji,et al.  Exploring mTOR inhibition as treatment for mitochondrial disease , 2019, Annals of clinical and translational neurology.

[35]  S. Kalko,et al.  Deoxynucleoside Therapy for Thymidine Kinase 2–Deficient Myopathy , 2019, Annals of neurology.

[36]  D. Lynch,et al.  New developments in pharmacotherapy for Friedreich ataxia , 2019, Expert opinion on pharmacotherapy.

[37]  R. Samulski,et al.  Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9. , 2019, Human gene therapy.

[38]  F. Scaglia,et al.  Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy , 2019, American journal of medical genetics. Part A.

[39]  Robert W. Taylor,et al.  Recent advances in understanding the molecular genetic basis of mitochondrial disease , 2019, Journal of inherited metabolic disease.

[40]  W. Stanford,et al.  The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Voyager’s CNS gene therapy , 2019, Nature Biotechnology.

[42]  Phillip G. D. Ward,et al.  Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in friedreich ataxia , 2019, Movement disorders : official journal of the Movement Disorder Society.

[43]  B. Byrne,et al.  AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome. , 2019, Human gene therapy.

[44]  B. Byrne,et al.  AAV9-TAZ Gene Replacement Ameliorates Cardiac TMT Proteomic Profiles in a Mouse Model of Barth Syndrome , 2019, Molecular therapy. Methods & clinical development.

[45]  Haiyan Jiang,et al.  Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 , 2019, Nature Medicine.

[46]  F. Mingozzi,et al.  The Alpha-1-Antitrypsin Promoter Improves the Efficacy of an AAV Vector for the Treatment of MNGIE. , 2019, Human gene therapy.

[47]  B. Bax,et al.  Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far , 2018, Front. Genet..

[48]  F. Pompei,et al.  Overcoming bioethical, legal, and hereditary barriers to mitochondrial replacement therapy in the USA , 2018, Journal of Assisted Reproduction and Genetics.

[49]  Christopher A. de Solis,et al.  The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons in vivo and Regulated via Doxycycline and Cre-Recombinase , 2018, Front. Mol. Neurosci..

[50]  J. Lyu,et al.  A Novel NDUFS3 mutation in a Chinese patient with severe Leigh syndrome , 2018, Journal of Human Genetics.

[51]  F. Piguet,et al.  Rapid and Complete Reversal of Sensory Ataxia by Gene Therapy in a Novel Model of Friedreich Ataxia. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  W. Hwu,et al.  Management of Leigh syndrome: Current status and new insights , 2018, Clinical genetics.

[53]  V. Tiranti,et al.  Response to medical and a novel dietary treatment in newborn screen identified patients with ethylmalonic encephalopathy. , 2018, Molecular genetics and metabolism.

[54]  V. Porciatti,et al.  Longterm Reversal of Severe Visual Loss by Mitochondrial Gene Transfer in a Mouse Model of Leber Hereditary Optic Neuropathy , 2018, Scientific Reports.

[55]  M. Gambello,et al.  MPV17‐related mitochondrial DNA maintenance defect: New cases and review of clinical, biochemical, and molecular aspects , 2018, Human mutation.

[56]  Robert W. Taylor,et al.  Retrospective natural history of thymidine kinase 2 deficiency , 2018, Journal of Medical Genetics.

[57]  Qiang Wang,et al.  The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  M. Zeviani,et al.  Long-Term Sustained Effect of Liver-Targeted Adeno-Associated Virus Gene Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy. , 2018, Human gene therapy.

[59]  Yukihiro Okada,et al.  Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain , 2018, Neuroscience Letters.

[60]  D. Corey,et al.  Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat. , 2018, Nucleic acid therapeutics.

[61]  R. Yadak,et al.  Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE , 2018, Molecular therapy. Methods & clinical development.

[62]  P. Giunti,et al.  Friedreich’s ataxia: clinical features, pathogenesis and management , 2017, British medical bulletin.

[63]  M. Zeviani,et al.  AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome , 2017, Gene Therapy.

[64]  D. Hernandez,et al.  SLC25A46 Mutations Associated with Autosomal Recessive Cerebellar Ataxia in North African Families , 2017, Neurodegenerative Diseases.

[65]  V. Gradinaru,et al.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems , 2017, Nature Neuroscience.

[66]  D. Geschwind,et al.  Inducible and reversible phenotypes in a novel mouse model of Friedreich’s Ataxia , 2017, bioRxiv.

[67]  E. Barca,et al.  Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency , 2017, Annals of neurology.

[68]  N. Muzyczka,et al.  AAV: An Overview of Unanswered Questions. , 2017, Human gene therapy.

[69]  G. Panayotou,et al.  Novel insights into SLC25A46-related pathologies in a genetic mouse model , 2017, PLoS genetics.

[70]  M. Kılıç,et al.  Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine , 2017, Metabolic Brain Disease.

[71]  N. Darín,et al.  Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes , 2017, Journal of Inherited Metabolic Disease.

[72]  P. Lockhart,et al.  Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. , 2016, Brain : a journal of neurology.

[73]  Nazanin Mirzaei,et al.  PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer’s disease model , 2016, Proceedings of the National Academy of Sciences.

[74]  R. Lodi,et al.  Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy , 2016, Annals of neurology.

[75]  L. W. Cole.  The Evolution of Per-cell Organelle Number , 2016, Front. Cell Dev. Biol..

[76]  K. Bhatia,et al.  SLC25A46 mutations underlie progressive myoclonic ataxia with optic atrophy and neuropathy , 2016, Movement disorders : official journal of the Movement Disorder Society.

[77]  J. Gottesfeld,et al.  Translating HDAC inhibitors in Friedreich’s ataxia , 2016, Expert opinion on orphan drugs.

[78]  E. Shoubridge,et al.  SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome , 2016, EMBO molecular medicine.

[79]  K. Lyseng-Williamson.  Idebenone: A Review in Leber’s Hereditary Optic Neuropathy , 2016, Drugs.

[80]  V. Tiranti,et al.  Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease. , 2016, Brain : a journal of neurology.

[81]  H. Smeets,et al.  Leigh syndrome: Resolving the clinical and genetic heterogeneity paves the way for treatment options. , 2016, Molecular genetics and metabolism.

[82]  S. Rahman,et al.  Leigh syndrome: One disorder, more than 75 monogenic causes , 2016, Annals of neurology.

[83]  Robert W. Taylor,et al.  MPV17 Loss Causes Deoxynucleotide Insufficiency and Slow DNA Replication in Mitochondria , 2016, PLoS genetics.

[84]  Sripriya Ravindra Kumar,et al.  Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain , 2015, Nature Biotechnology.

[85]  J. Barquinero,et al.  Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. , 2016, Human gene therapy.

[86]  W. Hauswirth,et al.  Consequences of zygote injection and germline transfer of mutant human mitochondrial DNA in mice , 2015, Proceedings of the National Academy of Sciences.

[87]  H. Mandel,et al.  Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. , 2015, Brain : a journal of neurology.

[88]  R. Schüle,et al.  Mutations in the UGO1-like protein SLC25A46 cause an optic atrophy spectrum disorder , 2015, Nature Genetics.

[89]  A. Paetau,et al.  Leigh Syndrome: Neuropathology and Pathogenesis , 2015, Journal of neuropathology and experimental neurology.

[90]  Suhua Chang,et al.  Mutations in apoptosis-inducing factor cause X-linked recessive auditory neuropathy spectrum disorder , 2015, Journal of Medical Genetics.

[91]  Robert W. Taylor,et al.  Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease , 2015, Annals of neurology.

[92]  C. Gérard,et al.  An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models , 2014, Molecular therapy. Methods & clinical development.

[93]  E. Barca,et al.  Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy. , 2014, Brain : a journal of neurology.

[94]  R. Crystal,et al.  Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia , 2014, Nature Medicine.

[95]  M. Zeviani,et al.  AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  Matt Kaeberlein,et al.  mTOR Inhibition Alleviates Mitochondrial Disease in a Mouse Model of Leigh Syndrome , 2013, Science.

[97]  P. Tonin,et al.  Clinical/Scientific Notes , 2011, Neurology.

[98]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[99]  M. Ashworth,et al.  Barth syndrome , 2013, Orphanet Journal of Rare Diseases.

[100]  F. Scaglia,et al.  Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic Options , 2013, Neurotherapeutics.

[101]  V. Tiranti,et al.  Altered sulfide (H(2)S) metabolism in ethylmalonic encephalopathy. , 2013, Cold Spring Harbor perspectives in biology.

[102]  E. Shoubridge,et al.  MITRAC Links Mitochondrial Protein Translocation to Respiratory-Chain Assembly and Translational Regulation , 2012, Cell.

[103]  M. Zeviani,et al.  Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy , 2012, EMBO molecular medicine.

[104]  W. Hauswirth,et al.  Mutant NADH dehydrogenase subunit 4 gene delivery to mitochondria by targeting sequence-modified adeno-associated virus induces visual loss and optic atrophy in mice , 2012, Molecular vision.

[105]  B. Ludwig,et al.  Role of Surf1 in heme recruitment for bacterial COX biogenesis. , 2012, Biochimica et biophysica acta.

[106]  W. Hauswirth,et al.  Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model , 2012, Proceedings of the National Academy of Sciences.

[107]  Clifford M. Babbey,et al.  A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. , 2012, Human molecular genetics.

[108]  V. Tiranti,et al.  Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy , 2012, Journal of Inherited Metabolic Disease.

[109]  C. Leborgne,et al.  A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[110]  B. Ravina,et al.  Mortality in Friedreich Ataxia , 2011, Journal of the Neurological Sciences.

[111]  J. Barquinero,et al.  Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE , 2011, Gene Therapy.

[112]  V. Tiranti,et al.  Chronic exposure to sulfide causes accelerated degradation of cytochrome c oxidase in ethylmalonic encephalopathy. , 2011, Antioxidants & redox signaling.

[113]  A. Andreu,et al.  Limited dCTP Availability Accounts for Mitochondrial DNA Depletion in Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) , 2011, PLoS genetics.

[114]  M. Sands.  AAV-mediated liver-directed gene therapy. , 2011, Methods in molecular biology.

[115]  Chi-Chao Chan,et al.  Gene therapy for ocular diseases , 2010, British Journal of Ophthalmology.

[116]  V. Tiranti,et al.  Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy , 2010, Nature Medicine.

[117]  M. Zeviani,et al.  Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. , 2010, American journal of human genetics.

[118]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  I. Nishino,et al.  Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. , 2009, Human molecular genetics.

[120]  V. Tiranti,et al.  Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy , 2009, Nature Medicine.

[121]  M. Zeviani,et al.  Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice , 2008, Human molecular genetics.

[122]  M. Zeviani,et al.  Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients. , 2009, Journal of hepatology.

[123]  Philip R. Johnson,et al.  Infectious Molecular Clones of Adeno-Associated Virus Isolated Directly from Human Tissues , 2008, Journal of Virology.

[124]  W. Dauer,et al.  Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. , 2008, Human molecular genetics.

[125]  M. Schwartz,et al.  Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. , 2007, Archives of neurology.

[126]  Massimo Zeviani,et al.  Increased longevity and refractoriness to Ca(2+)-dependent neurodegeneration in Surf1 knockout mice. , 2007, Human molecular genetics.

[127]  W. Hauswirth,et al.  The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. , 2007, Investigative ophthalmology & visual science.

[128]  H. McBride,et al.  Mitochondria: More Than Just a Powerhouse , 2006, Current Biology.

[129]  Sarah Calvo,et al.  MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion , 2006, Nature Genetics.

[130]  Robert W. Taylor,et al.  Mitochondrial DNA mutations in human disease , 2005, Nature Reviews Genetics.

[131]  A. Federico,et al.  Brain mitochondrial impairment in ethylmalonic encephalopathy , 2004, Journal of Neurology.

[132]  Paolo Gasparini,et al.  Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. , 2004, American journal of human genetics.

[133]  P. Bénit,et al.  Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome , 2004, Journal of Medical Genetics.

[134]  I. Nishino,et al.  Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. , 2004, Clinical chemistry.

[135]  D. Thorburn,et al.  Minimum birth prevalence of mitochondrial respiratory chain disorders in children. , 2003, Brain : a journal of neurology.

[136]  D. McCarty,et al.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.

[137]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[138]  J. Melki,et al.  Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits , 2001, Nature Genetics.

[139]  K. Fischbeck,et al.  Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. , 2000, Human molecular genetics.

[140]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[141]  U. Hellman,et al.  Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates , 1999, FEBS letters.

[142]  A. Ribes,et al.  Syndrome of encephalopathy, petechiae, and ethylmalonic aciduria. , 1997, Pediatric neurology.

[143]  J. Henzen.  Publisher's note , 1979, Brain Research.